XXXX in patients receiving anticancer chemotherapy and antiemetics.

@entity1 @entity5 @entity26 @entity900 @entity619 @entity1245 @entity148 @entity1769 @entity1576 @entity1363
@entity1245 lessen @entity148 and improve comfort in @entity5 @entity1 . @entity1363 is an effective @entity1245 with a rapid onset and short duration of action, properties that could permit its use in outpatient areas or in short but stressful situations. Two consecutive trials were undertaken to study @entity1363 as an adjunct in patients receiving anticancer chemotherapy. Each studied @entity1363 given as a short infusion 30 min prior to chemotherapy at dose levels ranging from 0.01 to 0.05 mg/kg. Trial I determined the safety, sedation, and dose of @entity1363 in @entity1 receiving chemotherapy of low to moderate emetic potential. Twenty-two @entity1 were entered. No significant @entity1576 or @entity26 desaturation was observed. At the optimal dose level (0.04 mg/kg), sedation began a median of 3 min following administration and continued for a median of 38 min. Sixty-four percent of @entity1 experienced mild sedation. Trial II studied the same doses of @entity1363 when used in combination with intravenous @entity1769 and @entity619 in @entity1 receiving @entity900 > or = 100 mg/m2. Nineteen @entity1 were entered; 79% experienced mild sedation. At the 0.04-mg/kg dose level, sedation began a median of 18 min following administration and continued for a median of 170 min. @entity1363 can be given safely to @entity1 receiving chemotherapy with and without concomitant antiemetics. The predictability and duration of its sedative effects suggest it can be used in outpatients.
